SLC10A2 and Hepatic fibrosis: Paradoxically, administration of an IBAT inhibitor to Cyp2c70 KO mice in this study prevented the development of cholangiopathy and liver fibrosis, despite increasing the hydrophobicity of the liver BAs to HI values similar to those of serum and bile BA samples analyzed in the obeticholic acid–treated Cyp2c70 KO mice (60).